Blood Res 2014; 49(2):
Published online June 25, 2014
https://doi.org/10.5045/br.2014.49.2.77
© The Korean Society of Hematology
1Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.
2Research Institute of Clinical Medicine, Chonbuk National University-Chonbuk National University Hospital, Jeonju, Korea.
3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Table 1 Proportion of cancer patients and eligibility criteria in major clinical trials regarding direct oral anticoagulants for the treatment of acute venous thromboembolism.
Blood Res 2014; 49(2): 77-79
Published online June 25, 2014 https://doi.org/10.5045/br.2014.49.2.77
Copyright © The Korean Society of Hematology.
Ho-Young Yhim, M.D. Ph.D.1,2, and Soo-Mee Bang, M.D. Ph.D.3
1Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.
2Research Institute of Clinical Medicine, Chonbuk National University-Chonbuk National University Hospital, Jeonju, Korea.
3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Table 1 . Proportion of cancer patients and eligibility criteria in major clinical trials regarding direct oral anticoagulants for the treatment of acute venous thromboembolism..